



Amebic Liver Abscess: Epidemiology, Laboratory Diagnosis, Clinical Manifestations, and Nursing Management-An Updated Review

Alqahtani Salem Faraj M¹, Mohammed Ayed Shitawi Al-Balawe², Essa Mulfi Khalawi Alharbi², Mashan Mashal Hubaylis Alharthi³, Ahmed Hameed Aladhab⁴, Nader Abdulhadi Aljoughani⁵, Hassn Dairem Alshahrani⁵, Wajb Ayed Alotaibi⁵, Faisal Nuairan Sakab Alshammari⁵, Shimah Alhelo Tamshan Alrowaily⁵, Widad Abdulrahman Ayed Al-Anzi⁶, Wejdan Saad Alshahrani⁶

Abstract:

Background: Amebic liver abscess is the most common extraintestinal manifestation of infection caused by *Entamoeba histolytica*. It remains a major public health problem in developing regions with inadequate sanitation and unsafe drinking water. The disease primarily affects adults, particularly males aged 18 to 50 years, and is associated with significant morbidity and potential mortality if complications occur. **Aim:** This review aims to provide an updated and comprehensive overview of amebic liver abscess, focusing on epidemiology, pathogenesis, clinical presentation, laboratory diagnosis, management strategies, complications, and the role of nursing and multidisciplinary care in improving patient outcomes. **Methods:** A structured narrative review approach was used, synthesizing published literature on amebic liver abscess, including epidemiological studies, clinical guidelines, and recent evidence on diagnostic and therapeutic approaches. Information was organized into thematic sections covering etiology, pathophysiology, clinical features, imaging, laboratory diagnosis, treatment, complications, and healthcare team involvement. **Results:** The review highlights that *E. histolytica* is transmitted via the fecal-oral route and leads to hepatic involvement through portal circulation spread. Clinical presentation typically includes fever, right upper quadrant pain, and systemic symptoms. Diagnosis relies on serology with high sensitivity and imaging modalities such as ultrasound, CT, and MRI. Metronidazole followed by luminal agents remains the standard treatment, with most patients responding within days. Percutaneous or surgical intervention is required in complicated cases. Despite favorable prognosis in uncomplicated disease, rupture and extrahepatic spread significantly increase mortality risk. **Conclusion:** Amebic liver abscess is a preventable and treatable condition with excellent outcomes when diagnosed early and managed appropriately. Strengthening public health measures, improving sanitation, and promoting multidisciplinary healthcare collaboration are essential to reduce disease burden and prevent complications.

¹ Ministry of National Guard Health Affairs (MNGHA), Saudi Arabia

² Drug and Psychotropic Substances Detection Committee, Madinah, Ministry of National Guard, Saudi Arabia

³ Health Affairs, Ministry of National Guard, Saudi Arabia

⁴ King Abdulaziz Hospital, Al-Ahsa, Ministry of National Guard, Saudi Arabia

⁵ Military School of Health Sciences, Ministry of National Guard, Saudi Arabia

⁶ Medical Center, Islamic University, Madinah, Saudi Arabia

Keywords: Amebic liver abscess, *Entamoeba histolytica*, epidemiology, diagnosis, metronidazole, multidisciplinary care, parasitic infection.

Introduction

Amebiasis is a significant parasitic disease caused by the protozoan *Entamoeba histolytica*, which is primarily transmitted through the fecal–oral route following the ingestion of infective cysts present in contaminated food or water.[1] The condition remains a major public health concern, particularly in regions with inadequate sanitation and limited access to clean water. The first documented diagnosis of amebiasis was reported by Sir William Osler in 1890, marking an important milestone in the recognition and understanding of this parasitic infection.[2] Since then, extensive research has contributed to the characterization of its epidemiology, clinical manifestations, diagnostic approaches, and therapeutic management. The clinical spectrum of amebiasis is highly variable, ranging from asymptomatic colonization to severe invasive disease. While many infected individuals remain symptom-free, others may develop gastrointestinal manifestations such as diarrhea, abdominal discomfort, and fever. In certain cases, the parasite invades extraintestinal tissues, resulting in more serious complications. Among these, amebic liver abscess represents the most frequent and clinically significant extraintestinal manifestation, accounting for substantial morbidity in affected populations. The progression from intestinal infection to hepatic involvement occurs when trophozoites penetrate the intestinal mucosa and disseminate through the portal circulation to the liver, where they induce tissue destruction and abscess formation.

Epidemiological evidence indicates that amebic liver abscess occurs predominantly among males between 18 and 50 years of age. The disease is especially prevalent in tropical and subtropical regions, including India, several African countries, Mexico, and parts of Central and South America, where environmental and socioeconomic factors facilitate transmission.[1] Clinical manifestations commonly emerge within two to four weeks following infection. Patients frequently present with fever and pain localized to the right upper quadrant of the abdomen, reflecting hepatic inflammation and abscess development. Additionally, approximately 10% to 35% of affected individuals experience concurrent gastrointestinal symptoms, including diarrhea and abdominal disturbances, which may provide important diagnostic clues.[3][4] Accurate diagnosis of amebiasis and its hepatic complications requires a comprehensive assessment that integrates clinical findings, epidemiological exposure history, radiological investigations, and serological testing. Imaging modalities play a critical role in identifying hepatic lesions, while serological assays assist in confirming invasive infection. Current therapeutic strategies emphasize prompt antimicrobial treatment, with metronidazole serving as the cornerstone of therapy for invasive disease. This is typically followed by the administration of a luminal amebicidal agent, such as paromomycin, to eradicate residual intestinal colonization and prevent recurrence. In most cases, medical management alone is sufficient to achieve favorable outcomes, whereas invasive procedures such as abscess aspiration or surgical intervention are reserved for selected patients with specific clinical indications or treatment complications.[5][6]

Etiology

Entamoeba histolytica is a pathogenic protozoan parasite and the primary causative agent of human amebiasis, a disease that continues to impose a substantial global health burden. It is estimated that this organism is responsible for nearly 40 million infections worldwide each year and contributes to as many as 100,000 deaths annually, making it one of the most significant parasitic causes of human morbidity and mortality.[7] The parasite is transmitted predominantly through the fecal–oral route, whereby infective cysts are ingested via contaminated food, water, or hands. Following ingestion, the cysts excyst within the gastrointestinal tract, releasing trophozoites that colonize the colon and, in some cases, invade intestinal and extraintestinal tissues. Several species of the genus *Entamoeba* are capable of infecting humans; however, important differences exist in their pathogenic potential. Among these species, *Entamoeba dispar* and *Entamoeba moshkovskii* are morphologically similar to *E. histolytica* and share comparable modes of transmission. Nevertheless, they are generally regarded as nonpathogenic organisms and are not associated with invasive disease. Individuals infected with these species often remain asymptomatic carriers and may unknowingly contribute to environmental contamination and continued transmission within communities.[7] The close morphological resemblance among these species has historically posed diagnostic challenges, emphasizing the importance of advanced laboratory techniques for accurate species identification and appropriate clinical management. Despite the diversity of *Entamoeba* species infecting humans, *E. histolytica* remains the only species conclusively recognized as a cause of clinically significant amebiasis. Its pathogenicity is attributed to a range of virulence factors that facilitate tissue invasion, host-cell destruction, immune evasion, and dissemination beyond the intestinal tract. These mechanisms enable the parasite to produce a spectrum of disease manifestations, ranging from asymptomatic intestinal colonization to severe invasive conditions such as amebic colitis and amebic liver abscess. From an epidemiological perspective, humans serve as the principal reservoir for *E. histolytica* infection. In addition to humans, non-human primates have been identified as the only other known natural hosts capable of harboring the parasite.[8] The restricted host range of *E. histolytica* highlights the central role of human-to-human transmission in maintaining the parasite's life cycle and underscores the importance of public health measures focused on sanitation, hygiene, and early detection to reduce the global burden of amebiasis.

Epidemiology

Amebic liver abscess represents the most common extraintestinal manifestation of infection with *Entamoeba histolytica*, although its occurrence varies considerably according to age, sex, geographic location, and environmental conditions. The disease is relatively uncommon among pediatric populations and is observed predominantly in adults. Epidemiological studies have consistently demonstrated a marked gender disparity, with men experiencing amebic liver abscess at rates approximately ten times higher than women. The highest incidence is reported among individuals between 18 and 50 years of age. Although the precise mechanisms underlying this gender difference remain incompletely understood, several hypotheses have been proposed. Potential contributing factors include the influence of sex hormones on immune responses, differences in susceptibility to invasive disease, and behavioral factors such as alcohol consumption, which may increase the risk of hepatic involvement and disease progression.[2] The global distribution of *E. histolytica* infection reflects substantial variation in socioeconomic conditions, sanitation infrastructure, and access to clean water. The parasite is endemic in many tropical and subtropical regions and remains a significant public health challenge in developing countries. High infection rates have been documented in India, numerous African nations, Mexico, and countries throughout Central and South America, where environmental and public health conditions facilitate ongoing transmission.[7] In contrast, the prevalence of invasive amebiasis is considerably lower in industrialized nations. Within the United States, most reported cases occur among immigrants, travelers, and refugees originating from endemic areas. Increased incidence has also been observed among populations residing near the United States–Mexico border, reflecting the continued influence of geographic and demographic factors on disease occurrence.

Environmental conditions play a critical role in the epidemiology of amebiasis. The risk of infection is greatest in communities characterized by inadequate sanitation systems, poor sewage disposal practices, and contaminated municipal water supplies.[7] These conditions facilitate the persistence and dissemination of infective cysts in the environment, thereby increasing opportunities for human exposure. Transmission most commonly occurs through the ingestion of food or water contaminated with fecal material containing viable cysts. Consequently, populations living in overcrowded settings or regions with limited access to safe drinking water are particularly vulnerable to infection. In addition to traditional fecal–oral transmission, alternative routes of spread have been recognized. Direct person-to-person transmission may occur through certain sexual practices, particularly oral–anal contact. This route has been identified as an important mode of transmission among men who have sexual intercourse with men, contributing to the persistence of infection even in areas where sanitation standards are relatively high.[9] Recognition of these transmission pathways is essential for implementing targeted prevention strategies and public health interventions. Although many individuals infected with *E. histolytica* remain asymptomatic or experience only intestinal manifestations, a small proportion develop invasive disease. Epidemiological evidence suggests that approximately 2% to 5% of patients with intestinal amebiasis ultimately progress to amebic liver abscess formation.[2] This complication occurs when trophozoites invade the colonic mucosa and subsequently disseminate through the portal venous circulation to the liver. While the overall proportion of affected individuals is relatively low, the potential severity of hepatic involvement highlights the importance of early diagnosis, effective treatment, and preventive measures aimed at reducing the transmission and burden of *E. histolytica* infection worldwide.

Pathophysiology

The pathophysiology of amebiasis is closely linked to the complex life cycle of *Entamoeba histolytica*, which was first comprehensively described by Clifford Dobell in 1928. The parasite exists in two distinct developmental forms: the infective cyst stage and the invasive trophozoite stage.[2] These stages play essential roles in transmission, survival, and disease progression. Human infection is initiated through the ingestion of mature quadrinucleate cysts, typically acquired from food or water contaminated with human fecal matter. Due to their resistance to environmental conditions and gastric acidity, cysts can survive passage through the stomach and subsequently reach the small intestine. Following ingestion, excystation occurs within the small intestine, resulting in the release of motile trophozoites. These trophozoites migrate to the large intestine, where they colonize the colonic lumen and mucosal surface. In the majority of infected individuals, trophozoites remain confined to the intestinal tract without causing significant tissue damage. During this stage, the organisms undergo replication and eventually transform into cysts that are excreted in the feces, thereby facilitating transmission to new hosts. Consequently, many infected individuals remain asymptomatic carriers while continuing to contribute to the spread of infection.

In a subset of patients, however, trophozoites acquire invasive properties that enable them to adhere to the colonic epithelium and penetrate the intestinal mucosa. The parasite produces various virulence factors, including proteolytic enzymes and cytotoxic molecules, which promote epithelial destruction and facilitate tissue invasion. As trophozoites disrupt the integrity of the intestinal barrier, localized inflammation develops, accompanied by direct cellular injury and ulcer formation within the colon. This invasive process stimulates a host immune response characterized by the recruitment of neutrophils and other inflammatory cells to the site of infection. Although this response is intended to contain the pathogen, it also contributes to collateral tissue damage and further exacerbates mucosal injury.[10][11] Once the intestinal barrier has been breached, trophozoites may gain access to the portal venous circulation and disseminate beyond the gastrointestinal tract. The liver represents the most common extraintestinal site of infection because it receives blood directly from the portal system. Upon reaching hepatic tissue, trophozoites trigger a robust inflammatory response and induce extensive cellular destruction. Progressive hepatocellular injury occurs through

both apoptotic and necrotic mechanisms, leading to localized areas of tissue liquefaction and necrosis.[12] Over time, these necrotic regions coalesce to form an amebic liver abscess, which is characterized by a cavity filled with necrotic debris and inflammatory material. The combination of direct parasitic cytotoxicity, host inflammatory responses, and hepatocyte death constitutes the fundamental pathological basis for liver abscess formation in invasive amebiasis.[10][11][12]

Toxicokinetics

The pathogenic behavior of *Entamoeba histolytica* is closely associated with its mechanisms of host cell interaction, tissue invasion, and subsequent hepatic damage. A key step in its pathogenic process involves adhesion to colonic epithelial cells through a specific galactose/N-acetyl-D-galactosamine (Gal/GalNAc) lectin. This surface lectin plays a central role in enabling the parasite to bind firmly to host tissues, resist mucosal clearance, and initiate cytotoxic effects. Once attachment is established, the organism exerts direct cytolytic activity, leading to disruption of epithelial integrity and induction of programmed cell death in mammalian cells through apoptosis.[10] Following mucosal invasion, trophozoites may enter the portal circulation and reach the liver, where they establish the characteristic lesion of amebic liver abscess. Within hepatic tissue, the parasites induce localized hepatocellular injury resulting in the formation of well-demarcated abscess cavities. These lesions are typically composed of liquefied necrotic material, cellular debris, and degenerated hepatocytes. The abscess environment is surrounded by a peripheral zone containing connective tissue, inflammatory cells, and variable numbers of trophozoites, reflecting both host immune response and parasite activity. A notable pathological feature of amebic liver abscesses is the relatively low number of detectable organisms within large necrotic lesions. This observation suggests that *E. histolytica* does not require extensive proliferation or direct cell-to-cell contact to cause significant tissue destruction. Instead, hepatocyte damage may be mediated through the release of cytotoxic molecules, proteolytic enzymes, and other virulence factors that contribute to progressive tissue breakdown. This indirect mechanism of injury results in extensive hepatic necrosis disproportionate to the parasite burden, highlighting the potent destructive capacity of *E. histolytica* even when present in limited numbers within affected tissues.[11][12]

History and Physical

Amebic liver abscess may manifest long after exposure, with presentation occurring months to years following travel to endemic regions. This delayed onset makes detailed epidemiological history essential for accurate clinical suspicion. Careful inquiry regarding prior residence, travel, or migration from endemic areas is critical, particularly in patients with compatible clinical features. In the United States, most cases are observed among Hispanic immigrant males aged between 20 and 40 years, reflecting both demographic and exposure-related patterns of disease distribution. The majority of symptomatic patients develop clinical features within 2 to 4 weeks after exposure. The most common manifestations include fever, dull pain localized to the right upper quadrant of the abdomen or epigastric region, and occasionally cough due to diaphragmatic irritation. The clinical presentation may vary, and some individuals exhibit a more subacute course characterized by weight loss and reduced frequency of fever or abdominal discomfort. Gastrointestinal involvement is also reported in approximately 10% to 35% of cases and may present as nausea, vomiting, abdominal cramps, diarrhea, constipation, or abdominal distension, reflecting concurrent intestinal infection.[2]

Several risk factors increase susceptibility to infection and progression to invasive disease. These include recent travel to tropical or subtropical regions where *Entamoeba histolytica* is endemic, malnutrition, immunosuppressed states, and chronic alcohol consumption. These factors may impair host immune defenses and facilitate parasite invasion and dissemination. Physical examination findings typically demonstrate hepatomegaly with localized tenderness, most commonly over the right upper quadrant or right intercostal spaces, corresponding to hepatic involvement. The degree of tenderness may vary depending on abscess size and location. While most patients present with stable vital signs, a minority may exhibit severe systemic compromise, including signs of sepsis or shock. Rarely, complications such as rupture of hepatic lesions or cysts may lead to acute deterioration, resulting in life-threatening conditions requiring urgent intervention [2].

Evaluation

The evaluation of amebic liver abscess requires an integrated approach that combines laboratory findings, imaging studies, clinical history, and serological confirmation. Laboratory investigations commonly reveal leukocytosis, reflecting systemic inflammatory response to infection. In addition, abnormalities in liver function tests are frequently observed, including elevated serum transaminases and increased alkaline phosphatase levels, indicating hepatic inflammation and biliary involvement. These findings, while nonspecific, support the presence of hepatic pathology and prompt further diagnostic assessment. Radiologically, amebic liver abscesses are most commonly located in the right hepatic lobe, consistent with portal venous blood flow distribution from the colon. Lesions typically measure between 2 and 6 cm in diameter, although larger abscesses may also occur depending on disease severity and duration. Imaging modalities such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) play a central role in detection and characterization of hepatic lesions. Although these modalities are highly sensitive for identifying liver abscesses, they are not specific for distinguishing amebic from pyogenic etiologies [12][13].




Fig. 1: Hepatic Amebic Abscess.

On ultrasound examination, amebic liver abscesses often appear as round or oval lesions with homogeneous, hypoechoic internal echotexture. This appearance reflects the liquefactive necrosis and absence of solid tissue within the abscess cavity. CT imaging typically demonstrates low-density hepatic lesions with a peripheral enhancing rim, representing the inflammatory capsule surrounding the necrotic center. In some cases, internal septations or fluid–solid levels may be present, indicating variable stages of liquefaction and debris accumulation. MRI provides further tissue characterization, with lesions appearing as low signal intensity on T1-weighted images and high signal intensity on T2-weighted images, consistent with fluid-rich necrotic content. The combination of epidemiological exposure, such as travel to or residence in endemic areas, along with compatible clinical features and characteristic imaging findings, strongly supports the diagnosis of amebic liver abscess. Serological testing is an important adjunct in confirming infection. Indirect hemagglutination assays demonstrate high diagnostic sensitivity exceeding 95%, although sensitivity varies depending on disease stage. During acute infection, sensitivity ranges from 70% to 80%, while it increases to more than 90% in the convalescent phase. However, false-negative results may occur within the first week of illness due to delayed antibody production.[13]

Stool microscopy has limited diagnostic value, with sensitivity reported between 10% and 40%, reflecting the intermittent shedding of organisms and difficulty in distinguishing pathogenic from nonpathogenic species.[13] Consequently, stool examination alone is insufficient for diagnosis. Aspiration of the abscess is generally not required for diagnosis or management. However, when performed for diagnostic uncertainty or therapeutic indications, aspiration typically yields a characteristic thick, odorless, chocolate-brown fluid commonly described as “anchovy paste.” This appearance reflects liquefied necrotic hepatocytes and inflammatory debris rather than purulent bacterial infection, helping to differentiate amebic abscesses from pyogenic liver abscesses.[12][14]

Treatment / Management

The management of amebic liver abscess is primarily medical, with antiparasitic therapy serving as the cornerstone of treatment. First-line therapy involves the use of nitroimidazole compounds, with metronidazole considered the standard agent. The recommended regimen is metronidazole 500 to 750 mg administered orally three times daily for a duration of 7 to 10 days. An alternative option is tinidazole, which can be given as a single daily dose of 2 g for 3 consecutive days, offering similar efficacy with improved compliance due to shorter treatment duration. Despite effective eradication of invasive trophozoites, nitroimidazole therapy does not eliminate intestinal colonization in a substantial proportion of patients, estimated at 40% to 60%. For this reason, treatment must always be followed by a luminal amebicidal agent to eradicate residual cysts in the intestinal tract and prevent recurrence or continued transmission. Commonly used luminal agents include paromomycin at a dose of 500 mg three times daily for 7 days or iodoquinol 650 mg three times daily for 20 days.[11] Concurrent administration of metronidazole and paromomycin is not recommended because paromomycin-induced gastrointestinal side effects, particularly diarrhea, may interfere with clinical assessment of therapeutic response and disease resolution. In most cases, symptomatic improvement is observed within 72 to 96 hours after initiation of appropriate therapy, reflecting rapid response of hepatic inflammation to antimicrobial treatment.[15] Although the majority of patients respond favorably to medical management, approximately 15% may fail to improve and require additional interventional procedures. Indications for invasive management include lack of clinical improvement after 5 to 7 days of adequate therapy, presence of large abscesses exceeding 5 cm in diameter, involvement of the left hepatic lobe due to increased risk of rupture, or suspicion of

bacterial superinfection. In such cases, percutaneous abscess drainage may be performed using either needle aspiration or catheter-based drainage techniques.[16]

Evidence suggests that percutaneous catheter drainage is more effective than needle aspiration, demonstrating higher success rates, more rapid reduction in abscess size, and faster resolution of symptoms.[17] Surgical intervention is reserved for complicated cases, particularly when abscesses are multiple, multiloculated, or located in regions that are not amenable to percutaneous access. It is also indicated when percutaneous drainage fails to achieve adequate source control or when secondary bacterial infection is present. Rupture of an amebic liver abscess into the peritoneal or pericardial cavity represents a life-threatening complication associated with severe outcomes such as amebic peritonitis, cardiac tamponade, and high mortality risk. These situations constitute surgical emergencies requiring immediate intervention.[18] When operative management is necessary, laparoscopic drainage is preferred over open surgical approaches. Laparoscopic techniques are associated with reduced postoperative pain, shorter hospitalization, faster recovery, and effective abscess clearance, making them the preferred surgical option when feasible.

Differential Diagnosis

The evaluation of amebic liver abscess requires systematic exclusion of other hepatic lesions that present similar clinical, laboratory, and radiological features. Accurate differentiation is essential because management strategies vary significantly depending on the underlying etiology and delayed or incorrect diagnosis may result in severe complications. A comprehensive differential diagnosis includes both infectious and non-infectious causes of liver lesions. Pyogenic liver abscess is one of the most important alternative diagnoses. It commonly develops secondary to ascending cholangitis, direct extension of intra-abdominal infections, or hematogenous spread from distant infectious sites. The most frequently implicated organisms include *Staphylococcus* and *Streptococcus* species, as well as enteric gram-negative bacteria such as *Escherichia coli* and *Klebsiella* species. Clinical presentation may overlap with amebic abscess, but pyogenic infections are more often associated with higher levels of systemic toxicity and positive blood cultures. Cholangitis represents another significant source of hepatic infection and must be considered, particularly in patients with biliary obstruction or gallstone disease. In such cases, clinical features of jaundice and biliary sepsis may help differentiate it from amebic disease. Parasitic conditions also form an important part of the differential diagnosis. Echinococcal liver disease, caused by *Echinococcus granulosus*, can produce cystic lesions that may rupture or become secondarily infected, mimicking abscess formation. Hydatid cysts are typically characterized by well-defined cystic structures with internal septations or daughter cysts, which assist in differentiation. Similarly, melioidosis caused by *Burkholderia pseudomallei* can lead to multiple abscesses and systemic infection, particularly in endemic regions of Southeast Asia and northern Australia [11].

Fungal abscesses, most commonly due to *Candida* species, are typically observed in immunocompromised patients, such as those with malignancy, diabetes, or undergoing chemotherapy. These lesions often present as multiple small abscesses rather than a solitary large lesion. Non-infectious conditions must also be considered. Hepatic trauma may result in hematoma formation that can resemble abscesses in imaging studies. Intra-abdominal infections such as diverticulitis, appendicitis, or bowel perforation may also lead to secondary hepatic involvement through portal circulation spread. Finally, malignant conditions, particularly hepatocellular carcinoma and metastatic liver disease, can present mass lesions with necrotic centers that mimic abscesses radiologically. These cases require careful evaluation using imaging characteristics, tumor markers, and biopsy when necessary to exclude malignancy. Overall, distinguishing amebic liver abscess from these conditions requires integration of clinical history, epidemiological risk factors, imaging findings, and laboratory testing to ensure accurate diagnosis and appropriate treatment selection [12].

Prognosis

The prognosis of amebic liver abscess is generally favorable when the condition is identified early and treated appropriately with anti-amebic therapy. In uncomplicated cases, most patients show rapid clinical improvement following initiation of nitroimidazole-based treatment, and complete recovery is common without the need for invasive procedures. Resolution of fever and abdominal pain typically occurs within a few days, while gradual radiological improvement follows over weeks. This favorable outcome reflects the high sensitivity of *Entamoeba histolytica* to metronidazole and related agents, as well as the effectiveness of adjunctive luminal therapy in preventing recurrence.[19] However, prognosis becomes significantly worse when complications develop, particularly rupture of the abscess into the peritoneal cavity. In such situations, the clinical course may be rapidly progressive and life-threatening. Even with surgical intervention, reported mortality rates range from 20% to 50%, largely due to severe peritoneal contamination, sepsis, and delayed presentation. Percutaneous catheter drainage is often preferred over open surgical procedures in these cases, as it is associated with better outcomes and reduced procedural risk.[19] Cardiac involvement represents a rare but highly fatal complication of amebic liver abscess. Rupture into the pericardial space can result in cardiac tamponade, a medical emergency associated with high mortality if not promptly recognized and treated. Despite advances in imaging and interventional techniques, outcomes remain poor once the pericardium is involved. Overall, prognosis depends heavily on early diagnosis, timely initiation of therapy, and rapid management of complications, emphasizing the importance of clinical vigilance and prompt intervention.

Complications

Amebic liver abscess can lead to a range of serious and potentially life-threatening complications, primarily related to rupture and dissemination of infection. One of the most significant complications is rupture into adjacent structures, including the pleural cavity, lungs, pericardium, or peritoneal space. Abdominal rupture may result in generalized peritonitis, which is associated with severe systemic inflammatory response, septic shock, and high mortality if not urgently managed. Thoracic complications may occur when the abscess extends superiorly through the diaphragm, leading to pleural effusion, empyema, or hepatobronchial fistula formation. Pulmonary involvement may present with cough, dyspnea, or expectoration of necrotic material. These complications reflect direct extension of infection and inflammatory damage across anatomical barriers. Cardiac complications, although rare, are among the most severe manifestations. Rupture into the pericardium can lead to acute pericarditis, pericardial abscess formation, and cardiac tamponade. Progressive involvement may also result in myocarditis, constrictive pericarditis, and congestive heart failure.[20] These conditions carry a very high mortality rate and require immediate recognition and emergency intervention. Less common but clinically important complications include thrombosis of the hepatic vein or inferior vena cava, resulting from inflammatory extension and vascular compression. In rare cases, hematogenous dissemination of trophozoites can occur, leading to metastatic infection in distant organs such as the brain, resulting in cerebral amebiasis. These complications are uncommon but associated with severe morbidity. Overall, complications of amebic liver abscess reflect the invasive potential of *E. histolytica* and underscore the importance of early diagnosis and aggressive management to prevent disease progression.

Consultations

The management of amebic liver abscess often requires coordinated multidisciplinary care to ensure accurate diagnosis, effective treatment, and timely management of complications. Collaboration between multiple specialties improves clinical outcomes, particularly in complex or severe cases. Gastroenterology consultation plays a central role in diagnosis, medical management, and follow-up care. Gastroenterologists assist in interpreting serological tests, imaging findings, and response to therapy, as well as guiding pharmacological treatment strategies. They are often the primary specialists involved in initial evaluation and ongoing disease monitoring. General surgery consultation becomes essential when complications arise, such as abscess rupture, failure of medical therapy, or need for operative drainage. Surgeons are also involved in managing peritoneal or pericardial involvement and in performing emergency interventions when life-threatening complications occur. Interventional radiology is a key specialty in the modern management of amebic liver abscess. Radiologists perform image-guided procedures such as percutaneous needle aspiration or catheter drainage, which are preferred alternatives to open surgery in many cases. Their role is particularly important in abscesses that are large, refractory to medical therapy, or at risk of rupture. Infectious disease specialists contribute to the optimization of antimicrobial therapy, ensuring appropriate drug selection, duration of treatment, and prevention of recurrence. They also assist in differentiating amebic infection from other infectious causes of hepatic lesions. Together, these consultations ensure comprehensive care, reduce complications, and support favorable patient outcomes through integrated multidisciplinary management [15].

Patient Education

Prevention of amebic liver abscess relies primarily on interrupting transmission of *Entamoeba histolytica* through improved hygiene, sanitation, and safe behavioral practices. The most important preventive strategy is reducing fecal contamination of food and water sources. Access to clean drinking water, proper sewage disposal, and hand hygiene are essential public health measures that significantly reduce infection risk in endemic regions. Patient education also plays a critical role in prevention. Individuals traveling to or living in endemic areas should be informed about the risks associated with contaminated food and water consumption. Advising patients to consume properly treated or boiled water and avoid raw or unwashed foods is a key preventive measure. Safe sexual practices are also important in reducing transmission, particularly among men who have sexual intercourse with men, where oral–anal contact represents a recognized route of infection. Education regarding barrier methods and hygiene practices is essential in reducing transmission in this population. At a broader level, the development of an effective vaccine against *E. histolytica* remains a potential long-term preventive strategy, particularly for high-risk populations in developing countries, including children who are disproportionately affected by poor sanitation and exposure risks. Historically, amebic liver abscess was associated with high mortality rates, but with modern diagnostic tools and effective pharmacological therapy, it is now largely a curable condition. Emphasizing early presentation and adherence to treatment is essential for preventing complications and improving long-term outcomes [2][3].

Other Issues

Amebic liver abscess is caused by infection with *Entamoeba histolytica*, a protozoan parasite transmitted through the fecal–oral route. The disease is most commonly observed in males aged 20 to 50 years and in individuals with a history of travel to or residence in endemic regions, including India, Africa, Mexico, and Central and South America. These epidemiological patterns are essential for clinical suspicion and early diagnosis. Clinical presentation is variable but typically includes fever, right upper quadrant abdominal pain, cough, weight loss, and a range of gastrointestinal symptoms such as diarrhea, nausea, and vomiting. The nonspecific nature of these symptoms often necessitates a high index of suspicion in at-risk populations. Diagnosis relies heavily on serological testing, which demonstrates high

sensitivity exceeding 95%, making it a valuable confirmatory tool. In contrast, stool microscopy has limited sensitivity, ranging from 10% to 40%, and is therefore insufficient for definitive diagnosis. Imaging modalities such as ultrasound, CT, and MRI typically reveal hypoechoic or low-density hepatic lesions. In cases where aspiration is performed, the characteristic finding is a thick, odorless, brown fluid described as “anchovy paste,” which is highly suggestive of amebic etiology. Treatment consists of metronidazole 500 to 750 mg administered three times daily for 7 to 10 days, followed by a luminal agent such as paromomycin to eliminate intestinal colonization. Concurrent use of metronidazole and paromomycin is avoided due to potential interference with clinical assessment. Interventional procedures such as aspiration or surgery are reserved for large abscesses, left lobe involvement, failure of medical therapy after 5 to 7 days, bacterial superinfection, or rupture into adjacent cavities. Complications include peritonitis, pleural effusion, cardiac tamponade, hepatic vein or inferior vena cava thrombosis, and rare dissemination to the brain or lungs. Prognosis is generally excellent with timely treatment, but outcomes worsen significantly with delayed diagnosis or rupture, underscoring the importance of early recognition and intervention [3].

Enhancing Healthcare Team Outcomes

The management of amebic liver abscess requires a structured interprofessional approach that integrates multiple healthcare disciplines to ensure timely diagnosis, effective treatment, and prevention of complications. Disease severity and clinical complexity determine the level of intervention required, making coordinated teamwork essential in reducing morbidity and mortality rates.[21] Laboratory services play a foundational role in early detection. Serum antigen detection and stool microscopy are commonly used initial diagnostic tools, and laboratory technologists are central to ensuring accuracy, quality control, and timely reporting of results. Their input directly influences early clinical decision-making and guides subsequent imaging and therapeutic interventions. Radiology services are critical in confirming diagnosis and guiding management. Interventional radiologists perform image-guided procedures such as percutaneous needle aspiration or catheter drainage, particularly in cases involving large or unresponsive abscesses. In more complex presentations, including multiloculated or anatomically inaccessible abscesses, general surgeons may be required to perform laparoscopic or open surgical drainage. This surgical input becomes essential when minimally invasive approaches are insufficient or when complications arise. Pharmacists contribute significantly to optimizing pharmacotherapy and ensuring patient safety. Many drugs used in the treatment of amebic liver abscess are associated with adverse effects that require careful monitoring. For instance, emetine, used as a second-line agent in resistant cases, carries risks of cardiotoxicity and neurologic toxicity, including cardiac arrhythmias and neuromuscular complications. Pharmacist involvement ensures appropriate dosing, drug interaction screening, and early identification of adverse drug reactions, thereby improving therapeutic safety.

Nursing staff play a vital role in both inpatient and outpatient care. Nurses monitor treatment response, assess symptom resolution, and ensure adherence to therapy. In addition, they are essential in patient education, particularly regarding hygiene practices, sanitation, and safe food handling. Their role extends to public health education, helping to reduce transmission in communities at risk. Nurses also provide follow-up monitoring to ensure complete recovery and early identification of recurrence or complications. Infectious disease specialists are often involved in complex or severe cases, particularly when complications such as rupture into the lungs, pleural cavity, pericardium, or abdomen occur. These situations require urgent multidisciplinary consultation, often involving cardiology or pulmonology depending on the site of involvement. Prompt specialist input is essential to guide advanced management strategies and emergency interventions. Evidence indicates that interventional drainage, when combined with medical therapy, improves outcomes in complex abscess cases compared with pharmacological treatment alone.[23] Therefore, collaboration between medical, surgical, radiological, and pharmaceutical teams is essential for optimal patient care. Overall, effective communication and care coordination across disciplines ensure timely diagnosis, reduce complications, and enhance patient safety. A patient-centered, team-based approach significantly improves clinical outcomes and reduces mortality in individuals with amebic liver abscess.

Conclusion

Amebic liver abscess remains a significant parasitic complication of *Entamoeba histolytica* infection, with substantial impact on global health, particularly in endemic regions with poor sanitation and limited access to clean water. The disease demonstrates a wide clinical spectrum ranging from asymptomatic intestinal colonization to severe invasive hepatic disease. Early recognition relies heavily on epidemiological risk assessment, clinical suspicion, and integration of laboratory and imaging findings. Advances in diagnostic modalities, especially serological testing and cross-sectional imaging, have improved early detection and reduced diagnostic uncertainty. Metronidazole-based therapy followed by luminal agents remains the cornerstone of treatment, with most patients achieving full recovery when therapy is initiated promptly. Invasive procedures such as percutaneous drainage or surgical intervention are reserved for complicated or refractory cases, emphasizing the importance of individualized management strategies. Despite generally favorable outcomes, complications such as rupture into the peritoneal or pericardial cavities can result in high mortality, highlighting the need for timely diagnosis and multidisciplinary management. The role of interprofessional collaboration is central in optimizing patient outcomes, involving clinicians, radiologists, pharmacists, nurses, and infectious disease specialists working in coordinated care pathways. Preventive strategies focused on sanitation, hygiene, safe water supply, and patient education remain essential in reducing disease burden.

Overall, amebic liver abscess is a largely curable condition when identified early, yet it continues to present significant challenges in resource-limited settings where transmission remains active.

References

1. Nasrallah J, Akhouni M, Haouchine D, Marteau A, Mantelet S, Wind P, Benamouzig R, Bouchaud O, Dhote R, Izri A. Updates on the worldwide burden of amoebiasis: A case series and literature review. *J Infect Public Health*. 2022 Oct;15(10):1134-1141.
2. Arellano-Aguilar G, Marín-Santillán E, Castilla-Barajas JA, Bribiesca-Juárez MC, Domínguez-Carrillo LG. A brief history of amoebic liver abscess with an illustrative case. *Rev Gastroenterol Mex*. 2017 Oct-Dec;82(4):344-348.
3. Salles JM, Salles MJ, Moraes LA, Silva MC. Invasive amoebiasis: an update on diagnosis and management. *Expert Rev Anti Infect Ther*. 2007 Oct;5(5):893-901.
4. Hoffner RJ, Kilagbalian T, Esekogwu VI, Henderson SO. Common presentations of amoebic liver abscess. *Ann Emerg Med*. 1999 Sep;34(3):351-5.
5. Lardiére-Deguelte S, Ragot E, Amroun K, Piardi T, Dokmak S, Bruno O, Appere F, Sibert A, Hoeffel C, Sommacale D, Kianmanesh R. Hepatic abscess: Diagnosis and management. *J Visc Surg*. 2015 Sep;152(4):231-43.
6. Wijewantha HS. Liver Disease in Sri Lanka. *Euroasian J Hepatogastroenterol*. 2017 Jan-Jun;7(1):78-81.
7. Kannathasan S, Muruganathan A, Kumanan T, de Silva NR, Rajeshkannan N, Haque R, Iddawala D. Epidemiology and factors associated with amoebic liver abscess in northern Sri Lanka. *BMC Public Health*. 2018 Jan 10;18(1):118. [
8. Stanley SL. Amoebiasis. *Lancet*. 2003 Mar 22;361(9362):1025-34.
9. Kannathasan S, Muruganathan A, Kumanan T, Iddawala D, de Silva NR, Rajeshkannan N, Haque R. Amoebic liver abscess in northern Sri Lanka: first report of immunological and molecular confirmation of aetiology. *Parasit Vectors*. 2017 Jan 07;10(1):14.
10. Albenmoussa A, Sanai FM, Singhal A, Babatin MA, AlZanbagi AA, Al-Otaibi MM, Khan AH, Bzeizi KI. Liver abscess presentation and management in Saudi Arabia and the United Kingdom. *Ann Saudi Med*. 2011 Sep-Oct;31(5):528-32.
11. Wuerz T, Kane JB, Boggild AK, Krajden S, Keystone JS, Fuksa M, Kain KC, Warren R, Kempston J, Anderson J. A review of amoebic liver abscess for clinicians in a nonendemic setting. *Can J Gastroenterol*. 2012 Oct;26(10):729-33.
12. Khim G, Em S, Mo S, Townell N. Liver abscess: diagnostic and management issues found in the low resource setting. *Br Med Bull*. 2019 Dec 11;132(1):45-52.
13. Wong WK, Foo PC, Olivos-Garcia A, Noordin R, Mohamed Z, Othman N, Few LL, Lim BH. Parallel ELISAs using crude soluble antigen and excretory-secretory antigen for improved serodiagnosis of amoebic liver abscess. *Acta Trop*. 2017 Aug;172:208-212.
14. Chang CY, Radhakrishnan AP. Amoebic liver abscess. *Rev Soc Bras Med Trop*. 2022;55:e0665.
15. Priyadarshi RN, Kumar R, Anand U. Amoebic liver abscess: Clinico-radiological findings and interventional management. *World J Radiol*. 2022 Aug 28;14(8):272-285.
16. Waghmare M, Shah H, Tiwari C, Khedkar K, Gandhi S. Management of Liver Abscess in Children: Our Experience. *Euroasian J Hepatogastroenterol*. 2017 Jan-Jun;7(1):23-26.
17. Cai YL, Xiong XZ, Lu J, Cheng Y, Yang C, Lin YX, Zhang J, Cheng NS. Percutaneous needle aspiration versus catheter drainage in the management of liver abscess: a systematic review and meta-analysis. *HPB (Oxford)*. 2015 Mar;17(3):195-201. [PMC free article]
18. Priyadarshi RN, Prakash V, Anand U, Kumar P, Jha AK, Kumar R. Ultrasound-guided percutaneous catheter drainage of various types of ruptured amoebic liver abscess: a report of 117 cases from a highly endemic zone of India. *Abdom Radiol (NY)*. 2019 Mar;44(3):877-885.
19. Kumar R, Anand U, Priyadarshi RN, Mohan S, Parasar K. Management of amoebic peritonitis due to ruptured amoebic liver abscess: It's time for a paradigm shift. *JGH Open*. 2019 Jun;3(3):268-269.
20. Nunes MC, Guimarães Júnior MH, Diamantino AC, Gelape CL, Ferrari TC. Cardiac manifestations of parasitic diseases. *Heart*. 2017 May;103(9):651-658.
21. Kouamé N, N'goan-Domoua AM, Akaffou E, Konan AN. [Multidisciplinary management of amoebic liver abscesses at the University Hospital of Yopougon, Abidjan, Côte d'Ivoire]. *Pan Afr Med J*. 2010;7:25
22. Kale S, Nanavati AJ, Borle N, Nagral S. Outcomes of a conservative approach to management in amoebic liver abscess. *J Postgrad Med*. 2017 Jan-Mar;63(1):16-20.
23. Lübbert C, Wiegand J, Karlas T. Therapy of Liver Abscesses. *Viszeralmedizin*. 2014 Oct;30(5):334-41.
24. Dr. Thomas-Augustin Brisson (1852-1937)]. *Union Med Can*. 1978 Jan;107(1):115.